Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature

Minardi, Daniele; Quaresima, Luigi; Santoni, Matteo; Bianconi, Maristella; Scartozzi, Mario; Cascinu, Stefano; Muzzonigro, Giovanni

doi:10.1007/s11934-014-0478-2

Cited by 13 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, sorafenib was proved to reverse TAMs to protumoral cells (Edwards and Emens 2010 ). Sunitinib is currently considered the standard of care for the first-line treatment of metastatic clear cell renal cell carcinoma (Minardi et al 2015 ). Moreover, several clinical trials have checked its efficiency in treatment of small lung carcinoma (Abdelraouf et al 2016 ), prostate cancer (Armstrong et al 2016 ), and thymic malignancies (Remon et al 2016 ), whereas sorafenib has been approved for the treatment of primary advanced renal cell carcinoma and advanced primary liver cancer (Pitoia and Jerkovich 2016 ).…”

Section: Transformation Of Tams Into M1 Proinflammatory Macrophagesmentioning

confidence: 99%

Tumor-Associated Macrophages as Target for Antitumor Therapy

Sawa-Wejksza

Kandefer‐Szerszeń

2017

Arch. Immunol. Ther. Exp.

176

132

View full text Add to dashboard Cite

It is well known that the microenvironment of solid tumors is rich in inflammatory cells that influence tumor growth and development. Macrophages, called tumor-associated macrophages (TAMs), are the most abundant immune cell population present in tumor tissue. Several studies have demonstrated that the density of TAMs is associated with a poor prognosis and positively correlates with tumor growth. Several studies have proved that TAMs may activate and protect tumor stem cells, stimulate their proliferation as well as promote angiogenesis and metastasis. Furthermore, TAMs-derived cytokines and other proteins, such as CCL-17, CCL-22, TGF-β, IL-10, arginase 1, and galectin-3, make a significant contribution to immunosuppression. Since TAMs influence various aspects of cancer progression, there are many attempts to use them as a target for immunotherapy. The numerous studies have shown that the primary tumor growth and the number of metastatic sites can be significantly decreased by decreasing the population of macrophages in tumor tissue, for example, by blocking recruitment of monocytes or eliminating TAMs already present in the tumor tissue. Moreover, there are attempts at reprogramming TAMs into proinflammatory M1 macrophages or neutralizing the protumoral products of TAMs. Another approach uses TAMs for anticancer drug delivery into the tumor environment. In this review, we would like to summarize the clinical and preclinical trials that were focused on macrophages as a target for anticancer therapies.

show abstract

Section: Transformation Of Tams Into M1 Proinflammatory Macrophagesmentioning

confidence: 99%

Tumor-Associated Macrophages as Target for Antitumor Therapy

Sawa-Wejksza

Kandefer‐Szerszeń

2017

Arch. Immunol. Ther. Exp.

176

132

View full text Add to dashboard Cite

show abstract

“…[3] In patients with metastatic disease, the 5-year survival rates are less than 10%. [4] It is very important to make early diagnoses and to find new targets for the treatment of RCC.…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of PYCR1 expression in renal cell carcinoma

Xie

Zheng

et al. 2019

Medicine

View full text Add to dashboard Cite

Pyrroline-5-carboxylate reductase 1 (PYCR1) is an enzyme involved in cell metabolism and is upregulated in cancer. However, the correlations of PYCR1 expression with the clinicopathological features and prognosis of renal cell carcinoma (RCC) remain unclear. The purpose of this study was to identify the expression of PYCR1 and its clinical relevance in RCC patients. PYCR1 mRNA expression differences between RCC and the adjacent normal renal tissues were assessed using the Cancer Genome Atlas database (TCGA). Subsequently, the expression of PYCR1 mRNA and protein were evaluated by quantitative real-time polymerase chain reaction, Western blot, and immunochemistry using 30 paired frozen samples of RCC and the adjacent normal renal tissues. The protein expression of PYCR1 was evaluated by immunostaining formalin-fixed, paraffin-embedded sections of RCC samples from 96 patients who underwent radical nephrectomy, and its relationship with clinical features were analyzed. Nonpaired t tests were used to statistically analyze the differences between the 2 groups. Cox univariable and multivariable analyses of overall survival (OS) among RCC patients were performed. The expression of PYCR1 mRNA was significantly upregulated in RCC tissues compared to adjacent normal renal tissues in the TCGA database ( P < .01). The area under the receiver operating characteristic curve value was 0.748. The expression of PYCR1 mRNA and protein was significantly upregulated in RCC compared with that in paired normal renal tissues ( P < .01). Higher PYCR1 levels were associated with metastasis ( P < .01). Kaplan–Meier survival curves indicated that higher PYCR1 expression was correlated with poorer OS. Therefore, PYCR1 may act as a novel prognostic marker and therapeutic target in the diagnosis and treatment of RCC.

show abstract

“…The individual measurements from up to five target lesions are then summed to derive the VTB for a patient at a particular time point. The objective of our study was to quantify play key roles in the pathogenesis of clear-cell RCC (3,4).…”

mentioning

confidence: 99%

Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy

Smith¹,

Zhang²,

Bryan³

et al. 2016

Radiology

View full text Add to dashboard Cite

Purpose To quantify initial changes in the vascular tumor burden (VTB), a measure of the area of vascularized tumor on computed tomographic (CT) images, and predict tumor response to antiangiogenic therapy in patients with metastatic renal cell carcinoma (RCC). Materials and Methods For this institutional review board-approved HIPAA-compliant secondary analysis of a prospective phase III trial, adult patients with digital CT images and metastatic clear-cell RCC treated with sunitinib were included (n = 275). Target lesions were selected by using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines, and the CT images obtained after one cycle of sunitinib therapy were evaluated in comparison with baseline images. Tumor-response software was created to quantify tumor metrics (length, area, VTB, and mean attenuation) and automate response assessment. Progression-free survival (PFS) in responders and nonresponders according to VTB criteria was compared by using the Cox proportional hazard ratio (HR). The intraclass correlation coefficient (ICC) was used to assess interobserver agreement among three readers evaluating 28 randomly selected patients. Results VTB criteria nonresponders (n = 120) according to the initial posttherapy CT study were 5.7 times more likely to experience progression of disease (HR = 5.70; 95% confidence interval [CI]: 4.07, 7.97; P < .001) than responders (n = 155). There was not a statistically significant difference in PFS between RECIST nonresponders (n = 255) and responders (n = 20; HR = 1.54; 95% CI: 0.85, 2.77; P = .148). In a patient-level analysis, interobserver agreement was very good for assessing percentage change in length, area, and VTB (ICC = 0.82 [95% CI: 0.67, 0.91], 0.89 [95% CI: 0.79, 0.94], and 0.88 [95% CI: 0.79, 0.94], respectively) but was very poor for assessing percentage change in mean attenuation (ICC = 0.17 [95% CI: -0.05, 0.45]). Conclusion A quantitative CT imaging biomarker designed to measure initial changes in the VTB separated patients into responders and nonresponders, each with significantly different PFS, and showed very good interobserver agreement in patients with metastatic RCC treated with sunitinib. RSNA, 2016 Online supplemental material is available for this article.

show abstract

Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature

Cited by 13 publications

References 69 publications

Tumor-Associated Macrophages as Target for Antitumor Therapy

Tumor-Associated Macrophages as Target for Antitumor Therapy

The clinical significance of PYCR1 expression in renal cell carcinoma

Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy

Contact Info

Product

Resources

About